QR678 and minoxidil are both used for androgenetic alopecia and patterned hair loss but they work through entirely different mechanisms, are administered differently, and suit different patient profiles. This blog covers what each one does, what the clinical evidence shows, where each one is limited, and how they are used together for better outcomes than either alone.
They are not competitors. They work at different levels of the same problem.
Minoxidil is a topical vasodilator applied daily to the scalp. QR678 is an injectable growth factor formulation delivered directly into the dermis at the follicular level. One improves blood supply to follicles. The other delivers the biological signals that drive follicle activity directly. Comparing them as if one replaces the other misses the point of both.
According to Dr Harikiran Chekuri, one of India’s pioneering plastic surgeons and hair restoration specialists, “Minoxidil and QR678 are not the same category of treatment. Minoxidil works on the environment around the follicle. QR678 works on the follicle itself. For patients who have plateaued on minoxidil or who want a faster, more targeted response, QR678 is not a replacement. It is the next layer. The best outcomes come from combining them.”
What Each One Does and How They Differ?
The mechanism, delivery, and evidence base are fundamentally different.
| Minoxidil | QR678 | |
| Type | Topical vasodilator | Injectable growth factor formulation |
| Mechanism | Dilates scalp blood vessels, improves oxygen and nutrient delivery to follicles | Delivers growth factors including FGF, VEGF, and IGF directly into the dermis to stimulate follicle activity |
| Administration | Applied topically twice daily by the patient | Intradermal injections by a clinician, 6 to 8 sessions spaced 3 weeks apart |
| Evidence base | Decades of RCT data, FDA-approved | Growing clinical evidence, India-developed, multiple peer-reviewed studies including direct comparisons with PRP |
| Onset | Visible change at 3 to 6 months with consistent use | Visible change from session 3 to 4, approximately 8 to 12 weeks |
| Duration | Results maintained only with continued daily use. Stops working when stopped | Results sustained up to 12 months post-course. Maintenance sessions extend longevity |
| Who it suits | Early to moderate androgenetic alopecia, first-line treatment, both sexes | Moderate hair loss, patients who have plateaued on minoxidil, women with hormonal hair loss, post-transplant support |
| Compliance | Requires daily application indefinitely | Clinic-based sessions, no daily home compliance required |
- Minoxidil’s strength is its evidence base: Decades of RCT data, FDA approval for both men and women, and a well-understood safety profile make it the standard first-line recommendation for androgenetic alopecia at Redefine.
- QR678’s strength is targeted delivery: Growth factors injected intradermally act directly on follicular biology, bypassing topical delivery limitations. A 2021 Journal of Cosmetic Dermatology study confirmed significant improvement in hair density as monotherapy, with superior outcomes when combined with minoxidil and finasteride
- The PRP comparison: A 2020 randomised study showed 100% hair fall reduction at 6 months with QR678, maintained at 1-year follow-up outperforming PRP on all measured outcomes. Learn more about QR678 Hair Treatment at Redefine
Who Should Use Which and When to Combine Them?
- Start with minoxidil if: Hair loss is early, the patient is treatment-naive, cost and convenience are priorities, or the patient is not ready for clinic-based sessions. It remains the most accessible and evidence-backed starting point
- Add or switch to QR678 if: Minoxidil has been used consistently for six or more months with plateau or insufficient response. The patient has compliance difficulty with daily topical application. Hair loss is moderate and a faster, more targeted response is the clinical goal
- QR678 suits women specifically: Minoxidil is effective in female pattern hair loss but carries the risk of unwanted facial hair with topical use. QR678 is administered precisely to the scalp with no systemic or surface spread concerns, making it a cleaner option for women. For more information, read Best Hair Loss Treatment in Hyderabad at Redefine
- Combining Three produces superior outcomes: The 2021 clinical study confirmed QR678 combined with minoxidil and finasteride outperformed monotherapy with any single agent. The combination addresses follicle environment (minoxidil), DHT suppression (finasteride), and direct follicle stimulation (QR678) simultaneously
- Post-transplant use: QR678 is used post-hair transplant to support graft survival and native follicle retention. Minoxidil serves a similar supportive role. Both are used concurrently in post-transplant protocols at Redefine
Most patients benefit from a sequenced approach starting with minoxidil, then layering in QR678 where needed. Understanding how minoxidil and finasteride compare is a useful starting point before any consultation.
The right combination for your hair loss depends on your pattern, stage, and treatment history. Book your consultation to find out what applies to you.
Why Choose Redefine for Hair Loss Treatment in Hyderabad?
At Redefine Hair Transplant and Plastic Surgery Centre, we offer QR678 and minoxidil as part of a structured, diagnosis-led hair loss treatment plan. Dr Harikiran Chekuri brings over 20 years and more than 20,000 procedures to every consultation. He is a Gold Medallist in Plastic Surgery from NTR University of Health Sciences, Paul Harris Fellow, and Vaidya Siromani awardee 2015. Redefine has been ranked No.1 Plastic Surgery Centre in the Twin States by the Times of India Health Survey for three consecutive years, 2019, 2020, and 2021.
Every hair loss consultation at Redefine begins with a scalp and density assessment before any treatment is recommended. The plan is built from what the examination confirms, not from what the patient requests or what is trending.
Your follicles deserve a plan based on their actual condition. Book your consultation today.
Frequently Asked Questions
Is QR678 better than minoxidil?
They work through different mechanisms and suit different needs. Minoxidil has a stronger long-term evidence base and is the standard first-line treatment. QR678 delivers growth factors directly to the follicle and produces faster visible response. Combined, they produce superior outcomes to either alone.
Can QR678 and minoxidil be used together?
Yes. A 2021 clinical study confirmed the combination of QR678 with minoxidil and finasteride outperformed any single modality in male androgenetic alopecia. The combination addresses multiple mechanisms simultaneously.
How many QR678 sessions are needed?
A standard course is 6 to 8 sessions spaced 3 weeks apart. Visible improvement typically begins from session 3 to 4. Maintenance sessions every 6 to 12 months sustain the result.
Does QR678 work for women?
Yes. QR678 is particularly suited to women because it is administered precisely to the scalp without the unwanted facial hair risk associated with topical minoxidil.
What happens if you stop minoxidil?
Hair loss resumes within three to six months of stopping. Minoxidil must be used continuously to maintain results. QR678 results are sustained for up to 12 months post-course before maintenance is needed.
Reference
- Shome D, Kapoor R, Doshi K, et al. Comparison of QR678 and QR678 Neo as Monotherapy and Combination Therapy with 5% Minoxidil and Oral Finasteride in Male Androgenetic Alopecia. Journal of Cosmetic Dermatology. 2021.
https://pubmed.ncbi.nlm.nih.gov/33864424/ - Kapoor R, Shome D, Vadera S, Ram MS. QR678 and QR678 Neo vs PRP: A Randomised, Comparative, Prospective Study. Journal of Cosmetic Dermatology. 2020.
https://pubmed.ncbi.nlm.nih.gov/32333510/ - PMC. Relative Efficacy of Minoxidil in Combination with Other Treatments for Androgenic Alopecia: A Network Meta-Analysis. 2023.
https://pmc.ncbi.nlm.nih.gov/articles/PMC10697753/
